Paratek Pharmaceuticals to Acquire Optinose for ~$330M, Expanding its Commercial Portfolio
Shots:
- Paratek has entered into a definitive merger agreement to acquire Optinose incl. its approved product, Xhance for ~330M, delisting it from NASDAQ; closing expected by mid-2025
- As per the deal, Optinose stockholders will receive $9/share in cash (50% premium as per Mar 19, 2025) & CVR of $5/share on achieving revenue milestones, where they will get $1/share if Xhance reaches $150M in net sales & $4/share if it reaches $225M before Dec 31, 2029
- XHANCE (fluticasone propionate) uses a proprietary exhalation delivery system (EDS) to precisely target inflammation sites for treating CRS, with or without nasal polyps
Ref: Paratek | Image: Optinose
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
